The LatAm In-Licensing Playbook: Decoding Kyowa Kirin’s Move with Knight

GALASHIELS & MARLOW, U.K. – September 29, 2026 – For multinational pharmaceutical companies, Latin America has long represented a paradox. It is a region of immense demographic potential and growing healthcare expenditure, yet it remains a labyrinth of fragmented regulatory frameworks, complex reimbursement models, and uneven diagnostic infrastructure. Navigating this terrain requires either a massive capital expenditure to build local operations from the ground up, or a highly strategic partnership with an established regional player.

Kyowa Kirin International has definitively chosen the latter.

The Japanese-headquartered global specialty pharmaceutical company recently announced an exclusive distribution agreement with Montreal-based Knight Therapeutics. The deal grants Knight the rights to seek regulatory approvals and commercialize POTELIGEO (mogamulizumab) across four of Latin America’s most critical markets: Argentina, Brazil, Colombia, and Mexico. The targeted therapy addresses mycosis fungoides (MF) and Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin’s lymphoma.

This transaction marks Kyowa Kirin's inaugural commercial expansion of mogamulizumab into Latin America. But beyond the immediate clinical implications, the deal serves as a masterclass in the modern "in-licensing playbook"—a strategy increasingly utilized by global innovators to penetrate high-potential emerging markets without absorbing the prohibitive overhead of a direct commercial footprint.

The Diagnostic Odyssey in Emerging Healthcare Systems

To understand the market potential of this partnership, one must first understand the clinical landscape of CTCL in Latin America. CTCL is a rare malignancy that presents and persists in the skin, characterized by the localization of cancerous T lymphocytes. Mycosis fungoides accounts for approximately 60% of all CTCL cases and is typically indolent, while Sézary syndrome is a much rarer (around 5%) and far more aggressive variant with high levels of blood involvement.

The most significant barrier to treating CTCL globally—but acutely so in Latin America—is the diagnostic delay. On average, it takes between two and seven years for individuals to receive a confirmed diagnosis.

In its early stages, MF manifests as red patches or plaques that closely mimic highly common, benign dermatological conditions like eczema or psoriasis. In healthcare systems where access to specialized dermatopathology and advanced molecular diagnostics (such as T-cell receptor gene rearrangement studies) is often concentrated in major urban centers, patients frequently endure years of misdiagnosis. They cycle through ineffective topical treatments while the disease stealthily progresses.

Céline Rhême, Cluster General Manager, Emerging Growth Markets at Kyowa Kirin, highlighted this specific regional challenge in the company's announcement. “CTCL is more common in this region than many realise, and further work is needed to identify unmet needs and therefore drive improvements in patient outcomes,” Rhême noted. “We have an opportunity, and a responsibility to change that. Through our proud partnership with Knight Therapeutics, we can help to increase patient access in Latin America, as part of our ongoing and relentless commitment to bring life-changing value and make people smile.”

The introduction of a targeted biologic therapy like POTELIGEO into these markets is not merely a commercial event; it often acts as a catalyst for systemic clinical change. The availability of an effective, late-line treatment incentivizes earlier disease detection, driving pharmaceutical companies to invest in physician education and diagnostic infrastructure to identify their addressable patient population.

Navigating Regulatory Labyrinths

The decision to partner with Knight Therapeutics underscores the sheer complexity of Latin American regulatory agencies. Unlike the centralized European Medicines Agency (EMA), Latin America requires a country-by-country approach, each with its own distinct idiosyncrasies, timelines, and bureaucratic hurdles.

Brazil’s ANVISA is notoriously rigorous. While it offers priority review pathways for rare diseases, standard drug approvals can stretch well beyond a year. Mexico’s COFEPRIS has modernized in recent years, implementing recognition pathways for drugs already approved by stringent authorities like the FDA or EMA, but it still demands meticulous localized filings. Colombia’s INVIMA and Argentina’s ANMAT present their own unique 12-to-18-month gauntlets.

Knight Therapeutics has built its entire business model on mastering these specific regional intricacies. By leveraging Knight’s established regulatory teams, Kyowa Kirin bypasses the steep learning curve and operational friction that typically delays market entry. Knight assumes the burden of adapting the global clinical dossier of POTELIGEO—a first-in-class humanized monoclonal antibody directed against the CCR4 protein—to meet the specific demands of ANVISA, COFEPRIS, INVIMA, and ANMAT.

As one regional healthcare analyst observed, "Innovators like Kyowa Kirin are realizing that a molecule's global efficacy data is only as good as the local team's ability to push it through four different, highly protective regulatory bodies. Knight acts as the essential translation layer between global science and local bureaucracy."

The Economics of Rare Oncology in Latin America

Beyond regulatory approval, the ultimate test for POTELIGEO in Latin America will be market access and reimbursement. The current standard of care for advanced CTCL in the region relies on older systemic therapies, including chemotherapy, retinoids, and occasionally histone deacetylase (HDAC) inhibitors, though availability is highly variable.

POTELIGEO offers a novel mechanism of action. By binding to CCR4—a protein consistently expressed on the cancerous cells in MF and SS—the drug increases the attraction of immune cells to destroy the malignancy. However, as a highly specialized biologic, it carries a price tag that will inevitably trigger intense scrutiny from Latin American health technology assessment (HTA) bodies.

Agencies like CONITEC in Brazil and the CSG in Mexico are tasked with balancing the clinical benefits of innovative therapies against constrained public healthcare budgets. Securing reimbursement in the public systems (such as Brazil's SUS or Mexico's IMSS) is a grueling process that often requires demonstrating clear cost-effectiveness and negotiating significant price concessions.

While the specific financial terms of the Kyowa Kirin and Knight agreement remain undisclosed—likely involving standard upfront licensing payments, regulatory milestones, and tiered royalties—Knight’s regional commercial viability will depend heavily on tiered pricing strategies and managed entry agreements. The company will likely need to navigate a bifurcated market, initially targeting private insurance networks and out-of-pocket markets while simultaneously engaging in the multi-year battle for public formulary inclusion.

Accelerating Rare Oncology Portfolios

For Knight Therapeutics, the acquisition of exclusive rights to POTELIGEO is a significant victory that accelerates its momentum as a premier distribution powerhouse in Latin America. It perfectly aligns with the company's strategy of in-licensing de-risked, globally approved assets to build a formidable specialty oncology portfolio.

By adding a first-in-class therapy for a rare, underserved lymphoma to its commercial bag, Knight not only diversifies its revenue streams across Argentina, Brazil, Colombia, and Mexico, but also strengthens its negotiating leverage with regional healthcare providers and payers.

Ultimately, the Kyowa Kirin and Knight Therapeutics partnership is a clear signal cutting through the noise of global pharmaceutical strategy. It demonstrates that the future of specialty medicine in emerging markets will not be dictated solely by the companies that discover the breakthroughs, but by the strategic alliances they form to ensure those breakthroughs actually reach the patients who have spent years waiting in the dark.